Clinical Trial Update: An Efficacy and Safety Study of AVR-RD-02 Compared to Enzyme Replacement Therapy for Treatment of Gaucher Disease Type 3 [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial evaluating AVR-RD-02 for Gaucher disease type 3 was withdrawn after being studied in Phase 2/3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gaucher Disease
• Gaucher Disease Type 3

Drugs mentioned

• AVR-RD-02

Snippet

Sponsor: AVROBIO | Conditions: Gaucher Disease, Type 3 | Phase 2, Phase 3 | Status: WITHDRAWN